150,000 Shares in Dyne Therapeutics, Inc. (NASDAQ:DYN) Bought by Integral Health Asset Management LLC

Integral Health Asset Management LLC purchased a new stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 150,000 shares of the company's stock, valued at approximately $3,534,000. Integral Health Asset Management LLC owned approximately 0.15% of Dyne Therapeutics at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Bank of New York Mellon Corp increased its position in shares of Dyne Therapeutics by 0.3% during the fourth quarter. Bank of New York Mellon Corp now owns 234,798 shares of the company's stock valued at $5,532,000 after buying an additional 698 shares during the period. Summit Investment Advisors Inc. lifted its position in Dyne Therapeutics by 9.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company's stock valued at $203,000 after purchasing an additional 721 shares during the period. KBC Group NV lifted its position in Dyne Therapeutics by 45.3% during the fourth quarter. KBC Group NV now owns 3,135 shares of the company's stock valued at $74,000 after purchasing an additional 978 shares during the period. E Fund Management Co. Ltd. lifted its position in Dyne Therapeutics by 11.8% during the fourth quarter. E Fund Management Co. Ltd. now owns 11,848 shares of the company's stock valued at $279,000 after purchasing an additional 1,249 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its holdings in Dyne Therapeutics by 11.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 21,575 shares of the company's stock valued at $508,000 after buying an additional 2,265 shares during the last quarter. Institutional investors own 96.68% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Piper Sandler dropped their target price on shares of Dyne Therapeutics from $53.00 to $48.00 and set an "overweight" rating for the company in a research report on Friday, February 28th. Chardan Capital reaffirmed a "buy" rating and issued a $50.00 price target on shares of Dyne Therapeutics in a research note on Friday, May 9th. HC Wainwright dropped their price objective on shares of Dyne Therapeutics from $46.00 to $38.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. JPMorgan Chase & Co. cut their price objective on shares of Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating on the stock in a research report on Friday, March 21st. Finally, BMO Capital Markets initiated coverage on shares of Dyne Therapeutics in a research note on Wednesday, March 12th. They issued an "outperform" rating and a $50.00 target price for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Dyne Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $46.85.

Insider Transactions at Dyne Therapeutics

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of Dyne Therapeutics stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total value of $36,242.10. Following the completion of the sale, the insider now directly owns 199,087 shares in the company, valued at $2,777,263.65. The trade was a 1.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 6,237 shares of company stock valued at $77,760 in the last quarter. Insiders own 14.14% of the company's stock.

Dyne Therapeutics Stock Performance

Shares of DYN stock traded up $0.09 on Friday, hitting $11.83. The stock had a trading volume of 2,185,589 shares, compared to its average volume of 1,679,246. The firm has a market capitalization of $1.34 billion, a price-to-earnings ratio of -3.32 and a beta of 1.19. The stock's 50 day moving average is $10.36 and its 200-day moving average is $17.43. Dyne Therapeutics, Inc. has a 52-week low of $6.36 and a 52-week high of $47.45.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.17). Equities analysts expect that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.